SAN FRANCISCO, CA --(Marketwired - December 18, 2015) - Before starting his own firm in July, Jason Napodano spent more than 12 years at Zacks Investment Research producing highly detailed small-cap biotechnology research. Today, as owner and senior analyst at BioNap Consulting, Napodano is doing much the same, but with more flexibility. He follows dozens of companies and continues to perform diligence on new names with the single goal of finding multibaggers. One of his themes is to take a biotech basket-of-stocks approach, since he knows some names will fail but the winners will move upward with momentum. In this interview with The Life Sciences Report , Napodano discusses small-cap names with the potential to power portfolios to extraordinary levels.
Included in this interview are: Rexahn Pharmaceuticals Inc. (
TLSR : When should an investor get concerned about a company going back to the market for more capital?
JN : Where you should have concern is when a company raises cash and then comes back to the market having burned that cash without making progress. It's totally understandable when investors get frustrated with companies that raise cash poorly, either with low-quality investors, or at the wrong time, or the wrong way. My advice is…
Continue reading this interview: Let Your Biotech Winners Ride Into Orbit: Jason Napodano of BioNap Consulting
About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
DISCLOSURE:
Rexahn Pharmaceuticals Inc., Can-Fite BioPharma Ltd., Biota Pharmaceuticals Inc. and BriaCell Therapeutics Corp. are sponsors of Streetwise Reports. Jason Napodano had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Napodano and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.
Jim Patrick Email contact
